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Purpose or Objective: To report the outcome of localized 
gastric lymphoma treated with radiation therapy. 
 
Material and Methods: This study included 27 patients (14 
men, 13 women; median age 67 years, range 37 – 83 years) 
with localized gastric lymphoma and who received radiation 
therapy between January 2005 and December 2014 at our 
institution. Patients with a follow-up period < 6 months were 
excluded. Twenty-three patients were mucosa-associated 
lymphoid tissue (MALT) lymphoma, and 4 patients were 
diffuse large B-cell lymphoma (DLBCL). The stage was 
classified by Lugano international conference classification. 
All patients with MALT lymphoma were Stage Ⅰ. In DLBCL, 2 
patients were Stage Ⅰ, and 2 patients were Stage Ⅱ1. The 
median radiation dose in MALT lymphoma was 30Gy (range, 
7.5–30), and in DLBCL was 40.5Gy (range, 30–40.5). All MALT 
lymphoma patients with Helicobacter pylori-positive were 
received eradication therapy before radiation therapy. All 
patients with DLBCL were treated with chemotherapy 
followed by radiation therapy. Acute and late adverse events 
were evaluated in accordance with Common terminology 
criteria for adverse events, version 4.0. The local recurrence 
rate was calculated using Kaplan-Meier analysis. 
 
Results: The median follow-up period was 58 months (range, 
6.0–120.0). Local recurrence occurred in only 2 patients with 
MALT lymphoma. No distant recurrence was observed. Local 
recurrence rate in MALT lymphoma was 91% at 1 year, 91% at 
3 years. In acute adverse events, 5 patients had grade 3 
white blood cell decreased, 1 patient had grade 4 white 
blood cell decreased and platelet count decreased, and 1 
patient had grade 3 anorexia. One patient with MALT 
lymphoma could not achieve the planned radiation therapy 
because of grade 4 white blood cell decreased and platelet 
count decreased. There was no grade 3 or greater late 
adverse events. One patient with MALT lymphoma suffered 
from gastric cancer, and underwent endoscopic excision. No 
patients died of gastric lymphoma. One patient died of lung 
cancer. 
 
Conclusion: Radiation therapy for localized gastric lymphoma 
was safe and effective. Our result was similar to previous 
reports. 
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Purpose or Objective: Radiation therapy (RT) is an important 
component of therapy for patients with Hodgkin (HL) and non 
Hodgkin lymphomas (NHL).  
In our retrospective analyze we showed the role of 
radiotherapy in treatment of lymphomas and its influence on 
disease free (DFS) and overall survival (OS) of patients. 
 
Material and Methods: From 2000 to 2010, we treated 347 
patients (pts) with lymphomas (Hodgkin - 286 and non 
Hodgkin - 61). There were 24 pts with stage I, 186 with stage 
II, 40 with stage III and 36 pts with stage IV of Hodgkin 
lymphoma. Among group of pts with non Hodgkin lymphoma 
there were 20 pts with stage I, 17 with stage II, 7 with stage 
III and 17 pts with stage IV. Sixty-nine percent of pts had 
favorable HL and 81% of pts nodular sclerosis as histological 
type. Sixty-four percent of pts with NHL had aggressive 
disease. Three dimensional conformal radiotherapy has been 
planned by computed tomography (CT) alone or by 18-FDG 
positron emission tomography/CT (18-FDG PET/CT). Mostly, 
patients received chemotherapy (95%) before RT. However, 
67% of pts with NHL did not receive rituximab.Whole group of 
our pts have been irradiated by involved field radiotherapy 
(IFRT). Most of patients received 36Gy (1.8-2Gy daily) (71%) 
and 29% more than 36Gy, in both groups. 
 
Results: Median follow-up time was 8 years. Among patients 
with HL, 33 pts (12%) had relapse and 11 pts (18%) with NHL. 
Relapses occur most often outside of irradiated volume in 
both groups of pts. Twenty five percent with HL patients had 
toxicity, most commonly pulmonary and 7% pts with NHL. 
During the median time of 13.5 years the incidence of a 
secondary malignancies (SM) was 3% in pts with HL and 2% 
with NHL. In group who had HL 91% of these pts lived and 74% 
in group with NHL. Ten-years DFS was 89% (HL) and 74% (NHL) 
and 10-years OS was 91% (HL) and 82% (NHL). 
 
Conclusion: Radiotherapy had an important place in the 
treatment of our patients with HL, as well as in a group of 
NHL with acceptable toxicity and incidence of secondary 
malignancies. 
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Purpose or Objective: To assess the incidence of second 
cancer in a mono-institutional cohort of long-time surviving 
Primary Mediastinal B Cell Lymphoma (PMBCL) patients 
treated with combined radio-chemo-immunotherapy. 
 
Material and Methods: Between 1991 and December 2006, 
107 consecutive untreated patients (pts) with PMBCL were 
treated at our Departments. Ninety-two/107 pts were 
evaluable for the second cancer incidence. All patients were 
treated with standard Methotrexate, Adriamycin, 
Cyclophosphamide, Vincristine, Prednisone and Bleomycin 
(MACOP-B) ± Rituximab; all patients underwent mediastinal 
radiation therapy (RT) at a dose of 30-36 Gy. 
 
Results: At the end of combined treatment, the overall 
response rate (ORR) including CR+Cru/PR was 91.3% while 7 
(7.6 %) patients showed progressive disease. Nine/84 (9.7%) 
patients relapsed within 10 months (range 3-10 months) from 
the end of therapy. After a median follow-up of 142 months 
(1-212 months), the actuarial 15-year OS and PFS were 87% 
and 84%, respectively. We recorded secondary malignancies 
in 3/80 long-surviving patients (3.75%) with cumulative 
incidence of thyroid and A acute myeloid leukemia of 3.47 at 
15 years and with a 20-year second cancer-free survival of 
82%. We observed 2 papillary thyroid cancers with a 
Standardized Incidence Ratio of 7.97 and with an Absolute 
Excess Risk of 17. 84. Moreover, we observed 1 Acute Myeloid 
Leukemia ( AML) versus 0.015 expected cases with a SIR of 
66.53 and with an AER of 10.05. No breast cancer occurred  
 
Conclusion: Combined modality treatment of chemotherapy± 
with/without Rituximab and mediastinal RT was related to a 
